CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nova Mentis Life Science Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nova Mentis Life Science Corp
700-838 West Hasting Street
Phone: (778) 819-0244p:778 819-0244 VANCOUVER, BC  V6C 0A6  Canada Ticker: NOVANOVA
Business Summary
Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board DerekIvany 1/18/2023 1/18/2023
President, Chief Executive Officer, Director WilliamRascan 5/16/2012 5/16/2012
Chief Financial Officer RebeccaHudson 12/30/2021 12/30/2021
Chief Operating Officer, Director JacquelineMcconnell 12/31/2021 9/17/2020
Chief Science Officer, Director StephenGlazer 9/30/2021 7/14/2021

Business Names
Business Name
1271642 B.C. Ltd.
HN3P
HN3Q
7 additional Business Names available in full report.

General Information
Outstanding Shares: 148,168,660 (As of 1/12/2024)
Stock Exchange: CNQ
Fax Number: (778) 819-0244


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024